Welcome to Tissue Regeneration Therapeutics (TRT)
Tissue Regeneration Therapeutics (TRT) is a Canadian life science company based on proprietary, and patented, human umbilical cord tissue technologies that provide a comprehensive product portfolio from skin care products to cell based, and cell engineered, therapeutics. TRT has discovered the world’s richest source of mesenchymal stromal/stem cells (MSCs) with potent regenerative, angiogenic, anti-inflammatory, and immuno-regulatory properties. Unique advantages of the TRT HUCPVC platform technology are founded on the highly enriched source of these important cells compared to other tissue sources.
WHAT WE DO
We Build Very Powerful Biology
With our partners we create cellular and regenerative strategies that maximize the utility of our platform technology and products – for therapies that address important health care issues of today. Together, we build very powerful biology.
A Progressive Biotechnology Company
Tissue Regeneration Therapeutics (TRT) is a progressive biotechnology company with a focus on the commercial development of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology and its TXP cell therapy products.
Toronto, ON (June 17, 2021) – J. E. Davies, President and CEO of Tissue Regeneration Therapeutics …
University of Toronto scientists Dr. Christopher Ward and Rita Gill win the prestigious “2021 …
Tissue Regeneration Therapeutics receives Certificate of Patent for Canadian Patent Application No. …